Abstract This report evaluates the therapeutic potential and safety of Ganodermalucidum (Lingzhi) in managing Type 2 Diabetes Mellitus (T2DM). The primary bioactive components, polysaccharides (GLP), demonstrate hypoglycemic effects by enhancing antioxidant enzyme activity and modulating apoptosis-related proteins (eg, bcl-2) to protect pancreatic beta-cells. Clinical studies indicate that 12 weeks of supplementation with Lingzhi extracts significantly reduces hemoglobin A1c (HbA1c) and fasting blood glucose levels. From a safety perspective, Lingzhi is traditionally classified as a non-toxic "superior herb" with benefits in preventing cardiovascular complications. While generally well-tolerated, some users may experience temporary "healing reactions" or potential anticoagulation effects during long-term use. Experts emphasize that Lingzhi should serve as a complementary therapy and must not replace conventional pharmacological treatments. The relationship between Ganoderma lucidum and diabetes is mainly reflected in the effects of its active ingredients (especially polysaccharides) on lowering blood sugar, regulating insulin secretion, and protecting the pancreas. Analysis of the relationship between Ganoderma lucidum and diabetes